Chi Shang Tai
Director/Miembro de la Junta en ZICOM GROUP LIMITED .
Perfil
Chi Shang Tai is the founder of Histoindex Pte Ltd.
He currently holds a position as a Non-Independent Non-Executive Director at Zicom Group Ltd.
Dr. Tai has an undergraduate and doctorate degree from Auckland University.
Cargos activos de Chi Shang Tai
| Empresas | Cargo | Inicio |
|---|---|---|
| ZICOM GROUP LIMITED | Director/Miembro de la Junta | 30/11/2020 |
Histoindex Pte Ltd.
 Histoindex Pte Ltd. Medical SpecialtiesHealth Technology Histoindex Pte Ltd. is a medtech/healthcare company based in Singapore, Singapore. The stain-free AI platform is currently involved in multiple FDA clinical trials for nonalcoholic steatohepatitis (NASH) and has benefitted more than 150 research and academic institutes, CROs, and biopharma companies worldwide in drug discovery and development efforts for fibrotic diseases and cancers. Founded in 2010, the Singaporean company specializes in its proprietary integrated stain-free AI digital pathology platform that accurately quantifies histological features and fine measurements critical for the evaluation of therapeutic efficacy in clinical trials. The company was founded by Gideon Ho, Chi-Shang Tai, and Gideon Ho has been the CEO since incorporation. | Fundador | 01/04/2010 |
Formación de Chi Shang Tai.
| Auckland University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ZICOM GROUP LIMITED | Producer Manufacturing |
| Empresas privadas | 1 |
|---|---|
Histoindex Pte Ltd.
Histoindex Pte Ltd. Medical SpecialtiesHealth Technology Histoindex Pte Ltd. is a medtech/healthcare company based in Singapore, Singapore. The stain-free AI platform is currently involved in multiple FDA clinical trials for nonalcoholic steatohepatitis (NASH) and has benefitted more than 150 research and academic institutes, CROs, and biopharma companies worldwide in drug discovery and development efforts for fibrotic diseases and cancers. Founded in 2010, the Singaporean company specializes in its proprietary integrated stain-free AI digital pathology platform that accurately quantifies histological features and fine measurements critical for the evaluation of therapeutic efficacy in clinical trials. The company was founded by Gideon Ho, Chi-Shang Tai, and Gideon Ho has been the CEO since incorporation. | Health Technology |
- Bolsa de valores
- Insiders
- Chi Shang Tai
